Single-layer oral dose of neuro-attenuating ketamine
The present invention is directed to oral neuro-attenuating ketamine (NAKET) tablet formulations, and methods of administration, which ensure the steady release of a therapeutically effective concentration of ketamine from an oral tablet without neurologically toxic spikes in ketamine concentration. In particular, the present invention provides single layer oral tablet formulation of NAKET. In a specific embodiment, the NAKET tablet formulation, and methods of administration provide steady administration of NAKET to a subject for 24 hours or greater, for example, up to 36 hours, after a single administration event.
1. A single-layer orally administered tablet composition comprising a combination of (i) a water-insoluble neutrally charged non-ionic matrix; (ii) a polymer carrying one or more negatively charged groups; and (iii) ketamine.
2. The tablet composition of claim 1 , wherein the composition is adapted for maximum sustained release.
3. The tablet composition of claim 1 , wherein the non-ionic matrix is selected from cellulose-based polymers, alone or enhanced by mixing with components selected from the group consisting of starches; waxes; neutral gums; polymethacrylates; PVA; PVA/PVP blends; and mixtures thereof.
4. The tablet composition of claim 1 , wherein the cellulose-based polymer is hydroxypropyl methylcellulose (HPMC).
5. The tablet composition of claim 1 , wherein the polymer carrying one or more negatively charged groups is selected from the group consisting of polyacrylic acid, polylactic acid, polyglycolic acid, polymethacrylate carboxylates, cation-exchange resins, clays, zeolites, hyaluronic acid, anionic gums, salts thereof, and mixtures thereof.
6. The tablet composition of claim 5 , wherein the anionic gum is selected from the group consisting of naturally occurring materials and semi-synthetic materials.
7. The tablet composition of claim 6 , wherein the naturally occurring material is selected from the group consisting of alginic acid, pectin, xanthan gum, carrageenan, locust bean gum, gum arabic, gum karaya, guar gum, and gum tragacanth.
8. The table composition of claim 6 , wherein the semi-synthetic material is selected from the group consisting of carboxymethyl-chitin and cellulose gum.
9. The tablet composition of claim 1 , comprising an amount of ketamine therapeutically effective for the treatment of pain.
10. The tablet composition of claim 1 , comprising an amount of ketamine therapeutically effective for use in the treatment of brain injury.
11. The tablet composition of claim 1 , comprising an amount of ketamine therapeutically effective for the treatment of depression.
12. The tablet composition of claim 1 , wherein the ketamine achieves a combined concentration of ketamine and its metabolite norketamine in plasma in the range of 10-500 ng/ml, and maintains this concentration for duration of the release period.
13. A method of continuous infusion oral administration of ketamine comprising the steps of formulating ketamine into a single-layer tablet that provides a steady release of a therapeutically effective concentration of ketamine from an oral tablet over a complete release period with no psychotomimetic toxic spikes in plasma ketamine concentration, to produce a single-layer tablet composition comprising a combination of (i) a water-insoluble neutrally charged non-ionic matrix; (ii) a polymer carrying one or more negatively charged groups; and (iii) ketamine; and orally administering the NAKET single-layer tablet composition to a subject, such that the NAKET provides a continuous therapeutically effective concentration of ketamine to the subject.
14. A method of formulating ketamine to ensure the steady release of a therapeutically effective concentration of ketamine from an oral tablet without psychotomimetic toxic spikes in plasma ketamine concentration comprising the step of combining (i) a water-insoluble neutrally charged non-ionic matrix; (ii) a polymer carrying one or more negatively charged groups; and (iii) ketamine, to produce an oral tablet composition.
15. A kit for the treatment of a subject with ketamine comprising a single-layer orally administered tablet composition of claim 1 , and instructions for use in the treatment of pain.
16. A kit for the treatment of a subject with ketamine comprising a single-layer orally administered tablet composition of claim 1 , and instructions for use in the treatment of brain injury.
17. A kit for the treatment of a subject with ketamine comprising a single-layer orally administered tablet composition of claim 1 , and instructions for use in the treatment of depression.